SKYE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Skye Bioscience Inc (SKYE) is not a good buy for a beginner, long-term investor at this time. The stock shows overbought conditions, lacks strong positive catalysts, and has legal and reputational risks. Additionally, the company's financial performance is weak, with no revenue growth and significant losses.
The MACD is positive and expanding, indicating bullish momentum. However, the RSI of 81.656 suggests the stock is overbought. Moving averages are converging, and the stock is trading near resistance levels (R1: 0.882, R2: 0.931). This indicates limited upside potential in the short term.
NULL identified. The stock has no strong trading trends from hedge funds or insiders, and there are no recent signals from Intellectia Proprietary Trading Signals.
Recent legal investigations and a federal securities lawsuit regarding the effectiveness of nimacimab could harm the company's reputation and investor confidence. Additionally, the stock is overbought, and there are no significant positive developments in the news.
In Q4 2025, the company reported no revenue growth (0% YoY) and a net loss of $14,441,963, though the loss improved by 48.18% YoY. EPS increased to -0.36, up 50.00% YoY. Gross margin remained at 0%. Overall, the financials indicate weak performance with no revenue generation.
No analyst rating or price target changes are available for SKYE at this time.
